Archives
Cohort Study | Risk of cancer after diagnosis of cardiovascular disease
25 Apr, 2023 | 14:29h | UTCRisk of Cancer After Diagnosis of Cardiovascular Disease – CardioOncology
Commentary: New details on the link between CVD and cancer, from a study of 27M patients – Cardiovascular Business
Sudden unexpected infant deaths in the US: 2015–2020
25 Apr, 2023 | 14:27h | UTCSudden Unexpected Infant Deaths: 2015–2020 – Pediatrics
Commentary:
Increasing Disparities in Sudden Unexpected Infant Deaths Reflect Societal Failures – Pediatrics
2020 spike in SIDS likely due to diagnostic shifting, not COVID-19 – Contemporary Pediatrics
Characteristics of fatal poisonings among infants and young children in the US
25 Apr, 2023 | 14:28h | UTC
Clinical Trial Update | Nivolumab plus Relatlimab for advanced melanoma fail to reach OS threshold despite PFS improvement
25 Apr, 2023 | 14:25h | UTCOverall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma – NEJM Evidence
Original Study: Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma – New England Journal of Medicine
Commentary on Twitter
Original Article: “Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma,” by Georgina V. Long, MD, PhD, et al. https://t.co/g5N1AYQV1I#OncoAlert #Melanoma
— NEJM Evidence (@NEJMEvidence) April 19, 2023
Cohort Study | Osmotic demyelination syndrome in patients hospitalized with hyponatremia
25 Apr, 2023 | 14:26h | UTCOsmotic Demyelination Syndrome in Patients Hospitalized with Hyponatremia – NEJM Evidence
RCT | Intraperitoneal carboplatin achieves modest PFS gains in advanced ovarian cancer
25 Apr, 2023 | 14:24h | UTCIntraperitoneal Carboplatin for Ovarian Cancer — A Phase 2/3 Trial – NEJM Evidence
Commentary on Twitter
“In the first-line treatment of advanced epithelial ovarian cancer, intraperitoneal carboplatin resulted in a modest prolongation of PFS [progression-free survival] when given with dose-dense weekly paclitaxel regardless of residual tumor size….”#MedTwitter #ClinicalTrials
— NEJM Evidence (@NEJMEvidence) April 23, 2023
SR | Angiogenesis inhibitors for the treatment of epithelial ovarian cancer
25 Apr, 2023 | 14:22h | UTCAngiogenesis inhibitors for the treatment of epithelial ovarian cancer – Cochrane Library
Brief Review | Diagnosis and management of adrenal insufficiency
25 Apr, 2023 | 14:18h | UTCDiagnosis and management of adrenal insufficiency – Clinical Medicine Journal
Brief Review | Diagnosis and management of neuroendocrine tumors
25 Apr, 2023 | 14:16h | UTCDiagnosis and management of neuroendocrine tumours – Clinical Medicine Journal
Brief Review | Management of pituitary incidentalomas
25 Apr, 2023 | 14:14h | UTCManagement of pituitary incidentalomas – Clinical Medicine Journal
Brief Review | Investigation and assessment of adrenal incidentalomas
25 Apr, 2023 | 14:13h | UTCInvestigation and assessment of adrenal incidentalomas – Clinical Medicine Journal
Brief Review | Thyroid disease in pregnancy
25 Apr, 2023 | 14:15h | UTCThyroid disease in pregnancy – Clinical Medicine Journal
Consensus Paper | Management of pathological thoracolumbar vertebral fractures in patients with multiple myeloma
25 Apr, 2023 | 14:11h | UTC
Geriatric odontoid fractures: treatment algorithms based on expert consensus and a systematic review
25 Apr, 2023 | 14:08h | UTC
USPSTF Statement | There is insufficient evidence to guide skin cancer screening recommendations
24 Apr, 2023 | 14:07h | UTCScreening for Skin Cancer: US Preventive Services Task Force Recommendation Statement – JAMA
Evidence Report: Skin Cancer Screening: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editorials:
Patient Page: Screening and Prevention of Skin Cancer – JAMA
Author Interview: USPSTF Recommendation: Screening for Skin Cancer – JAMA
Commentary on Twitter
2023 Recommendation Statement from the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of visual skin examination by a clinician to screen for #skincancer in adolescents and adults (I statement). https://t.co/WB6VN2r1Nv
— JAMA (@JAMA_current) April 18, 2023
WHO releases first-ever Standard on universal access to rapid TB diagnostics
24 Apr, 2023 | 14:04h | UTCNews Release: WHO releases first-ever Standard on universal access to rapid TB diagnostics – World Health Organization
WHO Standard: Universal access to rapid tuberculosis diagnostics – World Health Organization
RCT | Oral fluvoxamine plus inhaled budesonide reduced hospitalizations in high-risk patients with early-onset COVID-19
24 Apr, 2023 | 13:51h | UTC
Commentary on Twitter
Treatment w/ oral fluvoxamine + inhaled budesonide among high-risk outpatients w/ early #COVID19 reduced incidence of severe disease requiring advanced care. The combined effect seems to offer benefits over individual use of each drug: https://t.co/wM2da5a5MD pic.twitter.com/Sl1qFzTOjD
— Annals of Int Med (@AnnalsofIM) April 19, 2023
RCT | Bariatric–metabolic surgery is more effective than lifestyle intervention plus best medical care in non-alcoholic steatohepatitis
24 Apr, 2023 | 14:03h | UTCNews Release: Surgery most effective treatment of metabolic liver disease – King’s College London
Commentary on Twitter
New @TheLancet – Verrastro et al – Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trialhttps://t.co/pCWahvbReQ#NASH #NAFLD #fattyliver #livertwitter pic.twitter.com/xNMsAskJF9
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 21, 2023
RCT | Higher dose corticosteroids increase mortality in hypoxic COVID-19 patients on simple oxygen
24 Apr, 2023 | 13:55h | UTCEditorial: Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia? – The Lancet
Commentary: Higher-dose corticosteroids tied to 60% more deaths in low-oxygen COVID patients – CIDRAP
Commentary on Twitter (thread – click for more)
Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support.
A new study evaluated the use of a higher dose of corticosteroids in this patient group. https://t.co/uJGSYSBQAO
— The Lancet (@TheLancet) April 13, 2023
RCT | No difference in atrial fibrillation recurrence with early vs. delayed AF ablation at 12 months
24 Apr, 2023 | 13:49h | UTCImpact of Early Versus Delayed Atrial Fibrillation Catheter Ablation on Atrial Arrhythmia Recurrences – European Heart Journal (link to abstract – $ for full-text. Free PDF may be available here)
Commentary on Twitter
Early versus delayed ablation strategy in atrial fibrillation: read the impact on arrhythmia free survival on #EHJ!#EHRA2023 #EHJ #cardiotwitter #ablation #AF @ESC_Journals @escardio https://t.co/RW9RPry5Vi pic.twitter.com/2iHW49T3Wp
— EHJ Editor-in-Chief (@ehj_ed) April 18, 2023
Evidence Analysis | Blood pressure targets – how low can you get?
24 Apr, 2023 | 13:47h | UTCBlood pressure targets – how low can you get? – Evidently Cochrane
Original Article: SR | Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.
Commentary on Twitter
Blood pressure targets – how low can you get? https://t.co/ERLm6Mihl8 In this @CochraneUK blog, GP @rtwalton123 looks at the latest guidance & @CochraneLibrary evidence on what #BloodPressure targets to aim for, balancing the benefits of treatment against risk of side effects. pic.twitter.com/8EQH0JLzzc
— The Cochrane Library (@CochraneLibrary) April 19, 2023
Prehospital guidelines for the management of traumatic brain injury
24 Apr, 2023 | 13:45h | UTC
Guideline Update | Diagnosis and management of hypertension in pregnancy
24 Apr, 2023 | 13:43h | UTC
Immediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist
24 Apr, 2023 | 13:40h | UTCImmediate hypersensitivity reactions to antineoplastic agents – A practical guide for the oncologist- Cancer Treatment Reviews (free for a limited period)
See Tweet from one of the authors with infographic and link to free full text here
RCT | Panitumumab vs. Bevacizumab added to 1st-line chemo in RAS wild-type left-sided metastatic colorectal cancer
24 Apr, 2023 | 13:41h | UTCPanitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Anti-EGFR Therapy for Left-Sided RAS Wild-type Colorectal Cancer—PARADIGM Shift – JAMA Oncology (free for a limited period)
Commentary on Twitter
Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, vs bevacizumab, to standard first-line chemotherapy significantly improved overall survival in patients with left-sided tumors and in the overall population. https://t.co/Hjh9f3fN1z #AACR23 pic.twitter.com/uZxQUkfNbB
— JAMA (@JAMA_current) April 18, 2023